Gradia Health vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Metabolic health program combining continuous glucose monitoring with nutrition coaching; prediabetes prevention for employer wellness programs competing with Virta Health and Omada.
About
Gradia Health is a digital health company providing personalized metabolic health programs that combine continuous glucose monitoring (CGM), one-on-one nutrition coaching, and lifestyle interventions to prevent and reverse chronic metabolic conditions including prediabetes, insulin resistance, and metabolic syndrome. Founded in 2020 in San Francisco, Gradia raised $4.33-6.83 million in funding and generated $1.1 million in revenue in 2024, serving patients through both employer-sponsored health benefits and direct-to-consumer program enrollment.\n\nGradia's program pairs participants with a continuous glucose monitor that provides real-time blood sugar data, then connects them with registered dietitians and health coaches who use that data to personalize meal plans and behavioral interventions. The CGM data reveals how individual participants' blood sugar responds to specific foods, exercise, sleep, and stress — enabling precision nutrition recommendations that go beyond generic dietary guidelines. Programs typically run 3-6 months and focus on sustainable lifestyle changes supported by regular coach check-ins.\n\nIn 2025, Gradia operates in the rapidly growing metabolic health digital platform market alongside Levels Health (CGM for optimization), Virta Health (type 2 diabetes reversal), Noom (behavioral weight loss), and Omada Health (preventive health coaching) for the employer wellness and direct-to-consumer metabolic health programs. The employer-sponsored wellness market is particularly active as self-insured employers recognize that preventing metabolic disease is significantly cheaper than treating its downstream consequences (heart disease, type 2 diabetes, kidney disease). Gradia's 2025 strategy focuses on growing employer contracts with self-insured mid-market companies, deepening the CGM-based coaching methodology with AI-powered insights, and expanding the clinical evidence base for the program's outcomes.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.